Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lilly And Innovent’s Rituximab Gets Chinese Nod

Companies Continue To Collaborate On Oncology Biologics

Executive Summary

Eli Lilly and Chinese biotech specialist Innovent Biologics have received approval in China for their biosimilar rituximab, Halpryza. The companies are continuing to co-develop and commercialize other oncology medicines for the Chinese market.

You may also be interested in...



Henlius Seeks To Add RA Indication To Chinese Rituximab

Shanghai Henlius Biotech has filed with China’s NMPA to add a rheumatoid arthritis indication to its HLX01 approved rituximab biosimilar, despite the originator not being approved for RA in China.

Innovent’s Adalimumab And Bevacizumab Get New Indications In China

Chinese biotech specialist Innovent Biologics has received approval for new indications for its adalimumab and bevacizumab biosimilars from China’s NMPA. 

Kelix Strikes A Deal To Acquire 14 Oncology Injectables

Kelix bio has announced two deals to expand its presence in Africa. The company is set to acquire 14 oncology injectable products from Germany-based Vitane. Furthermore, Kelix has acquired Pharmaceutical Institute, a pharmaceutical company established in Rabat, to enter Morocco. The pan-African company has also invested in Malta.

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB150338

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel